Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Crucell, DSM Biologics Sign Pact with UMN Pharma | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Crucell, DSM Biologics Sign Pact with UMN Pharma

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Crucell N.V. and allied contract manufacturer DSM Biologics have signed a PER.C6 research license agreement with Japanese pharmaceutical company UMN Pharma. This license agreement allows UMN Pharma to use the PER.C6 cell line in its UMN-03 project, which aims to employ a fusion protein in the treatment of muscular dystrophy and metabolic diseases such as obesity and type II diabetes mellitus. Also, the two companies will provide UMN Pharma with various services including vector construction, clone generation, process development and cGMP manufacturing, through its own facilities in Groningen, The Netherlands and within the PER.C6 vendor network.

Under the terms of the agreement, UMN Pharma will pay a signing fee and annual maintenance fees. The additional services will also attract fees. Further financial details were not disclosed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics